Tirzepatide — 30 mg

Tirzepatide (LY3298176) is a synthetic 39-amino-acid peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The peptide incorporates a C20 fatty diacid moiety via a γGlu-(AEEA)₂ linker enabling reversible albumin binding and an extended pharmacokinetic profile compatible with once-weekly dosing. In published preclinical and clinical research, tirzepatide is investigated as a unimolecular agonist that engages both incretin pathways simultaneously, with research interest in glycemic endpoints, body composition, gastric emptying, and energy intake regulation in obesity and metabolic disease models. It is the first dual GIP / GLP-1 receptor agonist approved by the FDA (Mounjaro® 2022, Zepbound® 2023) and serves as the reference compound for the broader class of multi-incretin analogs.

Benefits (Research Focus)

• Dual receptor agonism — studied for simultaneous activation of GIP and GLP-1 receptors with imbalanced biased agonism

• Glycemic control research — investigated for fasting glucose, HbA1c, and insulin sensitivity parameters in T2D models

• Body composition — examined for fat-mass and lean-mass partitioning in obesity models

• Gastric emptying — explored for delayed gastric transit and downstream satiety endpoints

• Long-acting profile — C20 fatty diacid albumin-binding chemistry for extended half-life (~5 days)

What Researchers Look At

• Receptor binding affinity and selectivity at GIPR vs GLP-1R

• cAMP and β-arrestin recruitment in cell lines expressing each receptor subtype

• Food intake, body weight, and adipose-tissue change in DIO rodent models

• Gastric emptying time and gastrointestinal transit profiles

• Comparative pharmacology versus semaglutide, retatrutide, and other incretin analogs

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 30 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: Tirzepatide

• Synonyms: LY3298176; LY-3298176

• Class: Dual GIP / GLP-1 receptor agonist; long-acting incretin analog (39 amino acids)

• Modification: Lipidated with C20 fatty diacid via γGlu-(AEEA)₂ linker on Lys²⁰ residue; aminoisobutyric acid (Aib) substitutions at positions 2 and 13 for DPP-IV resistance

• Formula / M.W.: C₂₂₅H₃₄₈N₄₈O₆₈, ~4813.53 g/mol

• CAS: 2023788-19-2

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• Tirzepatide VPeptide — July 24, 2026 – Batch# ZE06-2730

• Tirzepatide 30mg VPeptide — August 14, 2026 – Batch# TIZ08-0530